Last reviewed · How we verify
NCT06634446: SCOPe
Self-administered COgnitive Personalized Training in Early Psychosis
NA trial testing a mobile application for cognitive training in First Episode Psychosis (FEP) in 240 participants. Currently enrolling.
30 December 2026
Quick facts
| Lead sponsor | Centre Hospitalier St Anne |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 240 |
| Start date | 26 October 2021 |
| Primary completion | 30 December 2026 |
| Estimated completion | 30 December 2027 |
| Sites | 1 location across France |
Drugs / interventions tested
- a mobile application for cognitive training
- video games
Conditions studied
- First Episode Psychosis (FEP) — all drugs for First Episode Psychosis (FEP) →
Sponsor
Centre Hospitalier St Anne
Who can join
Adults 16 to 35, any sex, with First Episode Psychosis (FEP). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall objective of SCOPe is to improve early intervention in psychosis by providing an innovative eHealth tool that will enable personalized cognitive training, adapted to the individual's cognitive abilities. Cognitive remediation improves quality of life and functional outcome in patients with chronic psychosis. It would even be more efficacious in the early phase of psychosis by tackling the negative impact of psychosis on education achievement and employment. However, cognitive dysfunctions are often overlooked in FEP and cognitive remediation is not always accessible. New technologies can provide us with youth-friendly, non-stigmatizing tools, such as self administered, training applications so that all first-line clinical settings or professionals, and in fine all patients, can have access, wherever they live, to personalized cognitive training focusing on impaired functions. Early psychosis can be associated with inflammation, metabolic deficiency, as well as early structural brain anomalies that reflect brain plasticity abilities and could influence the prognosis and response to cognitive training. Our background hypothesis is that promoting neuroplasticity by cognitive training could attenuate or reverse early cognitive deficits and improve the overall functional outcome in young patients experiencing FEP and that this effect is modulated by individual brain plasticity abilities.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06634446
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for First Episode Psychosis (FEP)
Currently open trials in the same condition.
- NCT06650943 — Nursing Intervention in Weight and Metabolic Syndrome Management in First-episode Psychosis (MetaKOP) · NA · recruiting
Other Centre Hospitalier St Anne trials
Trials by the same sponsor.
- NCT07340736 — Sensory Mechanisms of Manual Dexterity Recovery After Stroke: a Prospective Cohort Study of Prediction and Cerebral Corr · NA · not yet recruiting
- NCT07376473 — Psychometric Validation of the MQOL-FR and Descriptive Assessment of Quality of Life in Patients With Meningiomas · not yet recruiting
- NCT07395323 — Impact of Relaxation Sessions Using a Virtual Reality Application on the Sleep Quality of Caregivers Working Night Shift · NA · not yet recruiting
- NCT07283458 — Assessment of Language Comprehension and Learning in Children Attending Child Psychiatry Services (TICOALA-SOINS) · NA · not yet recruiting
- NCT07144956 — Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06634446 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier St Anne
- Last refreshed: 10 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06634446.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing